Skip to main content
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1984 Jan;25(1):49–52. doi: 10.1128/aac.25.1.49

Comparative efficacies of piperacillin, azlocillin, ticarcillin, aztreonam, and tobramycin against experimental Pseudomonas aeruginosa pneumonia.

J B Schiff, J E Pennington
PMCID: PMC185433  PMID: 6538397

Abstract

The therapeutic efficacies of the newer beta-lactam antibiotics piperacillin, azlocillin and aztreonam were compared with the efficacies of ticarcillin and tobramycin in a guinea pig model of experimental Pseudomonas aeruginosa pneumonia. For animals challenged with 2 X 10(8) CFU, tobramycin treatment resulted in survival rates and intrapulmonary killing of pseudomonads which were significantly greater than those found with any of the beta-lactam agents. There were no significant differences noted among the individual beta-lactam agents. When animals were challenged with 200-fold-fewer organisms (10(6) CFU), there was no significant difference between the efficacy of tobramycin and those of the various beta-lactams. These data suggest that tobramycin is particularly valuable in treating more severe P. aeruginosa pneumonia, whereas a number of different beta-lactam agents are of equivalent value in less severe lung infections.

Full text

PDF
49

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Broughton A., Strong J. E., Pickering L. K., Bodney G. P. Radioimmunoassay of iodinated tobramycin. Antimicrob Agents Chemother. 1976 Oct;10(4):652–656. doi: 10.1128/aac.10.4.652. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Corrado M. L., Landesman S. H., Cherubin C. E. Influence of inoculum size on activity of cefoperazone, cefotaxime, moxalactam, piperacillin, and N-formimidoyl thienamycin (MK0787) against Pseudomonas aeruginosa. Antimicrob Agents Chemother. 1980 Dec;18(6):893–896. doi: 10.1128/aac.18.6.893. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Eliopoulos G. M., Moellering R. C., Jr Antibiotic synergism and antimicrobial combinations in clinical infections. Rev Infect Dis. 1982 Mar-Apr;4(2):282–293. doi: 10.1093/clinids/4.2.282. [DOI] [PubMed] [Google Scholar]
  4. Fu K. P., Neu H. C. Piperacillin, a new penicillin active against many bacteria resistant to other penicillins. Antimicrob Agents Chemother. 1978 Mar;13(3):358–367. doi: 10.1128/aac.13.3.358. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Pennington J. E., Johnson C. E. Comparative activities of N-formimidoyl thienamycin, ticarcillin, and tobramycin against experimental Pseudomonas aeruginosa pneumonia. Antimicrob Agents Chemother. 1982 Sep;22(3):406–408. doi: 10.1128/aac.22.3.406. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Pennington J. E., Johnson C. E., Platt R. Third-generation cephalosporins in the treatment of pneumonia due to Pseudomonas aeruginosa in guinea pigs. J Infect Dis. 1982 Oct;146(4):567–567. doi: 10.1093/infdis/146.4.567. [DOI] [PubMed] [Google Scholar]
  7. Pennington J. E., Miler J. J. Evaluation of a new polyvalent Pseudomonas vaccine in respiratory infections. Infect Immun. 1979 Sep;25(3):1029–1034. doi: 10.1128/iai.25.3.1029-1034.1979. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Pennington J. E., Stone R. M. Comparison of antibiotic regimens for treatment of experimental pneumonia due to Pseudomonas. J Infect Dis. 1979 Dec;140(6):881–889. doi: 10.1093/infdis/140.6.881. [DOI] [PubMed] [Google Scholar]
  9. Pseudomonas aeruginosa infections: persisting problems and current research to find new therapies. Ann Intern Med. 1975 Jun;82(6):819–831. doi: 10.7326/0003-4819-82-6-819. [DOI] [PubMed] [Google Scholar]
  10. Stewart D., Bodey G. P. Azlocillin: in vitro studies of a new semisynthetic penicillin. Antimicrob Agents Chemother. 1977 May;11(5):865–870. doi: 10.1128/aac.11.5.865. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sykes R. B., Bonner D. P., Bush K., Georgopapadakou N. H. Azthreonam (SQ 26,776), a synthetic monobactam specifically active against aerobic gram-negative bacteria. Antimicrob Agents Chemother. 1982 Jan;21(1):85–92. doi: 10.1128/aac.21.1.85. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES